Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Relapse

Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia

Bone Marrow Transplantation volume 36, pages 67–70 (2005)Cite this article

Summary:

Relapse postautograft in acute myeloid leukaemia (AML), may in part arise from leukaemia cells present in the bone marrow (BM) inoculum, and the level of minimal residual disease (MRD) in BM harvests used for autografting may therefore be clinically important.We have used the WT1 transcript as a marker of MRD, which was quantitated by RQ-PCR, in the BM harvests of 24 patients receiving an ABMT for AML. ABL was used as a control gene with WT1 level being normalised to 105 copies of ABL per sample. Median WT1 level was 651 copies (range=113–32 700) for the 13 patients with relapse-free survival (RFS) of less than 5 years, and 174 (range=0–1900) for patients with RFS of over 5 years postautograft (P<0.04). The RFS was 10.5 months for patients with WT1 level of >2000 copies (n=5), and has not yet been reached for patients with WT1 level<2000 (n=21), at a median follow-up of 92 months (P<0.05). We show that elevated levels of MRD in BM harvests are associated with a higher relapse risk in patients autografted for AML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Burnett AK, Goldstone AH, Stevens RM et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700–708.

    Article  CAS  PubMed  Google Scholar 

  2. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217–223.

    Article  CAS  PubMed  Google Scholar 

  3. Cassileth PA, Andersen JW, Bennett JM et al. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group. Leukemia 1992; 6 (Suppl 2): 116–119.

    PubMed  Google Scholar 

  4. Brenner MK, Rill DR, Holladay MS et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–86.

    Article  CAS  PubMed  Google Scholar 

  5. Kreuzer KA, Saborowski A, Lupberger J et al. Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 2001; 114: 313–318.

    Article  CAS  PubMed  Google Scholar 

  6. Cilloni D, Gottardi A, De Micheli D et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115–2121.

    Article  CAS  PubMed  Google Scholar 

  7. Ogawa H, Tamaki H, Ikegame K et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698–1704.

    Article  CAS  PubMed  Google Scholar 

  8. Garg M, Moore H, Tobal K, Liu Yin JA . Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003; 123: 49–59.

    Article  CAS  PubMed  Google Scholar 

  9. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  10. Chomczynski P, Sacchi N . Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem 1987; 162: 156–159.

    Article  CAS  PubMed  Google Scholar 

  11. Grimwade D, Walker H, Oliver F et al. What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Medical Research Council Leukaemia Working Parties. Bone Marrow Transplant 1997; 19: 1117–1123.

    Article  CAS  PubMed  Google Scholar 

  12. Reichle A, Rothe G, Krause S et al. Transplant characteristics: minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia. Leukemia 1999; 13: 1227–1234.

    Article  CAS  PubMed  Google Scholar 

  13. Mizuta S, Ito Y, Kohno A et al. Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group. Bone Marrow Transplant 1999; 24: 777–784.

    Article  CAS  PubMed  Google Scholar 

  14. Gorin NC, Labopin M, Meloni G et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia 1991; 5: 896–904.

    CAS  PubMed  Google Scholar 

  15. Gorin NC, Aegerter P, Auvert B et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75: 1606–1614.

    CAS  PubMed  Google Scholar 

  16. Siehl JM, Thiel E, Leben R et al. Quantitative real-time RT-PCR detects elevated Wilms tumor gene (WT1) expression in autologous blood stem cell preparations (PBSCs) from acute myeloid leukemia (AML) patients indicating contamination with leukemic blasts. Bone Marrow Transplant 2002; 29: 379–381.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Dr David Osborne was a Leukaemia Research Fund Training Fellow.

Author information

Authors and Affiliations

  1. University Department of Haematology, Manchester Royal Infirmary, Manchester, UK

    D Osborne, L Frost, K Tobal & J A Liu Yin

Authors
  1. D Osborne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Frost
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Tobal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J A Liu Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J A Liu Yin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Osborne, D., Frost, L., Tobal, K. et al. Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia. Bone Marrow Transplant 36, 67–70 (2005). https://doi.org/10.1038/sj.bmt.1704992

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704992

Keywords

This article is cited by

Search

Advanced search

Quick links